Abstract
The exact cause of Alzheimers disease is still unknown; despite the dramatic progress in understanding. Most gene mutations associated with Alzheimers disease point to the amyloid precursor protein and amyloid β. The α-, β- and γ-secretases are the three executioners of amyloid precursor protein processing. Significant progress has been made in the selective inhibition of these proteases, regardless of the availability of structural information. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. Cholesterol lowering drugs and metal chelators are also in advanced clinical stages as disease modifiers. Successful trials demand either large cohorts or reliable markers for Alzheimers disease. Therefore, several radiomarkers are under investigation to support such clinical trials.
Keywords: alzheimers disease, secretase, copper, statine, aspartic protease, cholesterol, imaging
Current Medicinal Chemistry
Title: Drug Development and PET-Diagnostics for Alzheimers Disease
Volume: 12 Issue: 14
Author(s): Boris Schmidt, Hannes A. Braun and Rajeshwar Narlawar
Affiliation:
Keywords: alzheimers disease, secretase, copper, statine, aspartic protease, cholesterol, imaging
Abstract: The exact cause of Alzheimers disease is still unknown; despite the dramatic progress in understanding. Most gene mutations associated with Alzheimers disease point to the amyloid precursor protein and amyloid β. The α-, β- and γ-secretases are the three executioners of amyloid precursor protein processing. Significant progress has been made in the selective inhibition of these proteases, regardless of the availability of structural information. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. Cholesterol lowering drugs and metal chelators are also in advanced clinical stages as disease modifiers. Successful trials demand either large cohorts or reliable markers for Alzheimers disease. Therefore, several radiomarkers are under investigation to support such clinical trials.
Export Options
About this article
Cite this article as:
Schmidt Boris, Braun A. Hannes and Narlawar Rajeshwar, Drug Development and PET-Diagnostics for Alzheimers Disease, Current Medicinal Chemistry 2005; 12 (14) . https://dx.doi.org/10.2174/0929867054367130
DOI https://dx.doi.org/10.2174/0929867054367130 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic and Natural Lipase Inhibitors
Mini-Reviews in Medicinal Chemistry Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Small Molecules Targeting the NMDA Receptor Complex as Drugs for Neuropathic Pain
Mini-Reviews in Medicinal Chemistry Zebrafish: Predictive Model for Targeted Cancer Therapeutics from Nature
Current Cancer Drug Targets Technological Advances in Antigen Delivery and Synthetic Peptide Vaccine Developmental Strategies
Mini-Reviews in Medicinal Chemistry Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Current Drug Metabolism Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide)
Current Pharmaceutical Design The Effect of Dual-Task Testing on Balance and Gait Performance in Adults with Type 1 or Type 2 Diabetes Mellitus: A Systematic Review
Current Diabetes Reviews Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF) and its Possible Role in Tumour Progression During Malignant Transformation of Atrophic Epithelium in Oral Submucous Fibrosis
Current Angiogenesis (Discontinued) Clinical Effectiveness of a High Dose Versus the Standard Dose of Meropenem in Ventilator-associated Pneumonia Caused by Multidrugresistant Bacteria: A Randomized, Single-blind Clinical Trial
Infectious Disorders - Drug Targets The Immune System Regulation in Sepsis: From Innate to Adaptive
Current Protein & Peptide Science Neuroplasticity within the Mesoaccumbens Dopamine System and its Role in Tobacco Dependence
Current Drug Targets - CNS & Neurological Disorders An Improved and Simple Route for the Synthesis of 3-Quinuclidinone Hydrochloride
Letters in Organic Chemistry Neurocognitive and Psychiatric Markers for Addiction: Common vs. Specific Endophenotypes for Heroin and Amphetamine Dependence
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Platelets in the Alzheimer’s Disease Brain: do they Play a Role in Cerebral Amyloid Angiopathy?
Current Neurovascular Research Pharmacogenomics of Nicotine Dependence and Impact on Smoking Cessation
Current Pharmacogenomics Recent Progress in the Design and Discovery of RXR Modulators Targeting Alternate Binding Sites of the Receptor
Current Topics in Medicinal Chemistry 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued)